Abstract
Abnormalities of the EGF receptor and/or the related ERBB2 receptor occur in a significant proportion of cases of human breast cancer and are important influences in the behaviour of this tumour type. In this report we demonstrate by nucleic acid analysis and immunohistochemistry that the recently recognised third member of this gene family, ERBB3, shows a wide range of expression in breast cancer, and shows stronger immunoreactivity than that observed in normal tissue in 43 out of 195 cases (22%) of primary breast cancer. Overexpression of ERBB3 appears to result from increased levels of gene transcription since in none of the cell lines or primary cancers analysed did we find evidence of gene amplification. High expression of ERBB3 is positively associated with the presence of lymph node metastases, but there was no demonstrable relationship with patient survival in this series.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lemoine, N., Barnes, D., Hollywood, D. et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66, 1116–1121 (1992). https://doi.org/10.1038/bjc.1992.420
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.420
This article is cited by
-
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer
BMC Cancer (2018)
-
Membrane Protein Quantity Control at the Endoplasmic Reticulum
The Journal of Membrane Biology (2017)
-
C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth
Scientific Reports (2016)
-
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Molecular Cancer (2014)
-
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
British Journal of Cancer (2014)